bepotastine besilate: an antiallergic agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
bepotastine besylate : An organosulfonate salt obtained by combining equimolar amounts of bepotastine and benzenesulfonic acid. A topical, selective and non-sedating histamine (H1) receptor antagonist used for treatment of itching associated with allergic conjunctivitis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
bepotastine : An ether that is (S)-(4-chlorophenyl)(pyridin-2-yl)methanol in which the hydroxyl hydrogen is substituted by a 1-(3-carboxypropyl)piperidin-4-yl group. A topical, selective and non-sedating histamine (H1) receptor antagonist used (as its benzenesulfonate salt) for treatment of itching associated with allergic conjunctivitis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 164521 |
| CHEMBL ID | 1201759 |
| CHEBI ID | 31281 |
| SCHEMBL ID | 1287638 |
| MeSH ID | M0281812 |
| Synonym |
|---|
| 4-{4-[(s)-(4-chlorophenyl)(pyridin-2-yl)methoxy]piperidin-1-yl}butanoic acid benzenesulfonate |
| HY-A0015 |
| bepotastine (besilate) |
| betotastine besilate |
| tau-284 |
| bepomax |
| talion |
| bepotastine besilate |
| bepreve |
| tau-284ds |
| 1-piperidinebutanoic acid, 4-((4-chlorophenyl)-2-pyridinylmethoxy)- (s)-, monobenzenesulfonate |
| 4-((4-chlorophenyl)-2-pyridinylmethoxy)- (s)-1-piperidinebutanoic acid monobenzenesulfonate |
| (+)-(s)-4-(4-((4-chlorophenyl)(2-pyridyl)methoxy)piperidino)butyric acid monobenzenesulfonate |
| bepotastine |
| bepotastine besilate (jp17) |
| D01654 |
| bepotastine besylate (usan) |
| bepreve (tn) |
| 190786-44-8 |
| talion (tn) |
| bepotastine benzenesulfonate salt |
| CHEMBL1201759 |
| chebi:31281 , |
| bepotastine besylate |
| bepotastine besylate [usan] |
| unii-6w18mo1qr3 |
| 6w18mo1qr3 , |
| bepotastine benzenesulfonate |
| 1-piperidinebutanoic acid, 4-((s)-(4-chlorophenyl)-2-pyridinylmethoxy)-, benzenesulfonate (1:1) |
| 1-piperidinebutanoic acid, 4-((s)-(4-chlorophenyl)-2-pyridinylmethoxy)-, benzenesulphonate (1:1) |
| (+)-4-(4-((s)-(4-chlorophenyl)(pyridin-2-yl)methoxy)piperidin-1-yl)butanoic acid monobenzenesulfonate |
| (+)-4-(4-((s)-(4-chlorophenyl)(pyridin-2-yl)methoxy)piperidin-1-yl)butanoic acid monobenzenesulphonate |
| bepotastine besilate [who-dd] |
| bepotastine benzenesulphonate salt |
| bepotastine besilate [jan] |
| bepotastine besilate [orange book] |
| bepotastine benzenesulfonate salt [mi] |
| 4-((s)-(4-chlorophenyl)-2-pyridinylmethoxy)-1-piperidinebutanoic acid benzenesulfonate salt |
| 4-((s)-(4-chlorophenyl)-2-pyridinylmethoxy)-1-piperidinebutanoic acid benzenesulphonate salt |
| bepotastine besilate [mart.] |
| bepotastine besilate [vandf] |
| CS-0383 |
| S3037 |
| SCHEMBL1287638 |
| UDGHXQPQKQPSBB-BOXHHOBZSA-N |
| (s)-4-[4-[(4-chlorophenyl)(2-pyridyl)-methoxy]piperidino]butanoic acid monobenzenesulfonic acid salt |
| (s)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butanoic acid monobenzenesulfonic acid salt |
| benzenesulfonic acid;4-[4-[(s)-(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid |
| AC-24015 |
| (s)-4-(4-((4-chlorophenyl)(pyridin-2-yl)methoxy)piperidin-1-yl)butanoic acid compound with benzenesulfonic acid (1:1) |
| B5943 |
| DTXSID80172577 |
| AKOS025401655 |
| bepotastine besitate |
| bepotastine beslilate |
| mfcd01938491 |
| J-012325 |
| SW220161-1 |
| tau284 |
| Q27114261 |
| AS-17863 |
| 1-piperidinebutanoic acid, 4-[(s)-(4-chlorophenyl)-2-pyridinylmethoxy]-, benzenesulfonate (1:1) |
| HMS3885A05 |
| CCG-269988 |
| 190786-44-8 (besylate) |
| 4-{4-[(s)-(4-chlorophenyl)(pyridin-2-yl)methoxy]piperidin-1-yl}butanoic acid; benzenesulfonic acid |
| EN300-6495932 |
| Z2235802230 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Bepotastine has negligible affinity for receptors associated with undesirable adverse effects, including histamine H(3), α(1)-, α(2)-, and β-adrenergic, serotonin (5-HT(2)), muscarinic, and benzodiazepine receptors." | ( Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilate. Gow, JA; Klier, SM; McCue, SL; McNamara, TR; Salapatek, AM; Williams, JI, 2010) | 0.36 |
| "All three topical ophthalmic medications used in the study are safe and effective in the treatment of allergic conjunctivitis." | ( Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis. Ayyappanavar, S; Gangasagara, SB; Jayanthi, CR; Kumar, K; Mittal, P; Preethi, B; Rathod, BLS; Sridhar, S, 2021) | 0.62 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The purpose of this review is to examine published non-clinical literature on the antihistamine bepotastine besilate, including pharmacokinetic and pharmacologic properties." | ( Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilate. Gow, JA; Klier, SM; McCue, SL; McNamara, TR; Salapatek, AM; Williams, JI, 2010) | 0.36 |
| " Pharmacokinetic parameters, including maximum plasma concentration (C(max)) and area under the plasma concentration-time curve (AUC), were calculated." | ( Pharmacokinetic comparisons of bepotastine besilate and bepotastine salicylate in healthy subjects. Kim, KA; Park, JY, 2013) | 0.39 |
| " All pharmacokinetic parameters of bepotastine exhibited no significant differences between the two formulations." | ( Pharmacokinetic comparisons of bepotastine besilate and bepotastine salicylate in healthy subjects. Kim, KA; Park, JY, 2013) | 0.39 |
| "64 mg (test) formulations have comparable pharmacokinetic characteristics and that these two formulations meet the regulatory criteria for bioequivalence." | ( Pharmacokinetic comparisons of bepotastine besilate and bepotastine salicylate in healthy subjects. Kim, KA; Park, JY, 2013) | 0.39 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The apparent absorption rate constant (ka) of [(14)C]bepotastine in the small intestine was greatly increased by cyclosporin A and verapamil, especially in the distal portion, and the site-specific absorption of [(14)C]bepotastine disappeared." | ( Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate. Fukuda, H; Kamikozawa, Y; Ohashi, R; Sugiura, M; Tamai, I; Yabuuchi, H, 2006) | 0.33 |
| " Furthermore, the bepotastine salicylate-loaded tablet was prepared by the wet granulation method, and the dissolution and bioavailability in beagle dogs were evaluated compared to the bepotastine besilate-loaded commercial product." | ( Development of novel bepotastine salicylate salt bioequivalent to the commercial bepotastine besilate in beagle dogs. Cho, KH; Choi, HG, 2013) | 0.39 |
| " A new generic formulation of bepotastine has been developed in China, and information concerning bioavailability and pharmacokinetic properties in the Chinese population has not been reported." | ( Comparative fasting bioavailability of 2 bepotastine formulations in healthy male Chinese volunteers: an open-label, randomized, single-dose, 2-way crossover study. Hu, X; Liu, J; Shentu, J; Wu, G; Wu, L; Zhai, Y; Zheng, Y; Zhou, H; Zhu, M, 2014) | 0.4 |
| "The aim of the present study was to compare the bioavailability and pharmacokinetic properties of 2 tablet formulations of bepotastine, the 10-mg generic formulation (test) and a branded formulation (reference), in healthy male Chinese volunteers to obtain registration approval of the test formulation." | ( Comparative fasting bioavailability of 2 bepotastine formulations in healthy male Chinese volunteers: an open-label, randomized, single-dose, 2-way crossover study. Hu, X; Liu, J; Shentu, J; Wu, G; Wu, L; Zhai, Y; Zheng, Y; Zhou, H; Zhu, M, 2014) | 0.4 |
| Excerpt | Relevance | Reference |
|---|---|---|
| "5% bepotastine besilate at 15 minutes and 8 hours after dosing for CAC-induced nasal congestion, rhinorrhea, ear or palate pruritus, nasal pruritus, and summed nonocular composite symptom (NOCS) scores and also at 16 hours after dosing for nasal congestion and rhinorrhea." | ( Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge. Abelson, MB; Gomes, PJ; Gow, JA; McNamara, TR; Torkildsen, GL; Williams, JI, 2010) | 0.36 |
| "5% compared with placebo for the treatment of ocular itching and conjunctival hyperemia (redness) using the conjunctival allergen challenge (CAC) model of allergic conjunctivitis when dosed 16 h before a CAC test." | ( Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis. Abelson, MB; Gomes, PJ; Gow, JA; Kennedy, KS; McNamara, TR; Torkildsen, GL; Williams, JI, 2011) | 0.37 |
| " Eligible subjects (n=107) aged 10 years and older with a history of allergic conjunctivitis who had a reproducible positive reaction to a CAC were enrolled and dosed with test agent." | ( Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis. Abelson, MB; Gomes, PJ; Gow, JA; Kennedy, KS; McNamara, TR; Torkildsen, GL; Williams, JI, 2011) | 0.37 |
| Role | Description |
|---|---|
| H1-receptor antagonist | H1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. |
| anti-allergic agent | A drug used to treat allergic reactions. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| organosulfonate salt | Any organic salt prepared using an organosulfonic acid as the acid component. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (13.04) | 18.2507 |
| 2000's | 12 (26.09) | 29.6817 |
| 2010's | 22 (47.83) | 24.3611 |
| 2020's | 6 (13.04) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (10.60) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 18 (34.62%) | 5.53% |
| Reviews | 5 (9.62%) | 6.00% |
| Case Studies | 1 (1.92%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 28 (53.85%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||